Article of the Week, Suggested by the BPDCN International Registry
Immune Oncology Research Institute shared a post on LinkedIn:
“Article of the Week Suggested by the BPDCN International Registry – Astghik Voskanyan
Advances in understanding BPDCN biology have led to novel therapies, including BET inhibitors, which induce BPDCN cell apoptosis by disrupting TCF4. Future clinical studies may explore these agents. A bispecific monoclonal antibody targeting CD123 and CD3, XmAb14045, is also under investigation (NCT02730312). Key priorities outlined by the North American BPDCN Consortium include defining and utilizing minimal residual disease (MRD) testing, developing a BPDCN risk stratification scale, improving clinical trial access, and addressing the high cost of targeted therapies.”
Blastic Plasmacytoid Dendritic Cell Neoplasm
Authors: Akriti Jain, Kendra Sweet.
Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.
Other posts featuring Immune Oncology Research Institute on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023